喹啉-2-磺酸 | 6046-38-4

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 喹啉-2-磺酸
• 英文名称: quinoline-2-sulfonic acid
• 英文别名: Chinolin-2-sulfonsaeure；2-Sulfo-chinolin
• CAS: 6046-38-4
• 化学式: C₉H₇NO₃S
• mdl: MFCD10574744
• 分子量: 209.225
• InChiKey: ZKIHLVYBGPFUAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  喹啉-2-磺酸 、 2-氨基-5-二乙基氨基戊烷 在 zinc(II) chloride 作用下， 生成 N⁴,N⁴-diethyl-N¹-[2]quinolyl-1-methyl-butanediyldiamine
  参考文献：
  名称：

  DE615184

  摘要：

  公开号：
• 作为产物：
  描述：

  2-喹啉硫醇 在 硝酸 作用下， 生成 喹啉-2-磺酸
  参考文献：
  名称：

  Besthorn; Geisselbrecht, Chemische Berichte, 1920, vol. 53, p. 1021

  摘要：

  DOI：

文献信息

• PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES
  申请人：Italfarmaco, S.A.

  公开号：EP1602644A1

  公开（公告）日：2005-12-07

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH-CO-R12, where R12 is C1-C6 alkyl or C6-C10 aryl; R1 and R2 represent H or SO3R9, independently from one another, where R9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R3 is H or OH; and R4, R5, R6 and R7 represent H, an NR10R11 or NH-CO-R12 group, independently from one another; on the condition that (i) at least one of R1 or R2 is SO3R9, and (ii) at least one of R4, R5, R6 or R7 is an NR10R11 or NH-CO-R12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  一种具有化学式（I）的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H、OH、NR10R11，独立地，其中R10和R11分别代表H或C1-C6烷基或配方NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H、铵或碱金属或碱土金属的阳离子；R3为H或OH；R4、R5、R6和R7独立地代表H、NR10R11或NH-CO-R12基团；条件是（i）R1或R2中至少有一个为SO3R9，（ii）R4、R5、R6或R7中至少有一个为NR10R11或NH-CO-R12基团，或它们的药用可接受盐；以及药用可接受的赋形剂。
• Proteomic analysis
  申请人：The Scripps Research Institute of an Assignment

  公开号：US20020064799A1

  公开（公告）日：2002-05-30

  The present invention provides methods for analyzing proteomes, as cells or lysates. The analysis is based on the use of probes that have specificity to the active form of proteins, particularly enzymes and receptors. The probes can be identified in different ways. In accordance with the present invention, a method is provided for generating and screening compound libraries that are used for the identification of lead molecules, and for the parallel identification of their biological targets. By appending specific functionalities and/or groups to one or more binding moieties, the reactive functionalities gain binding affinity and specificity for particular proteins and classes of proteins. Such libraries of candidate compounds, referred to herein as activity-based probes, or ABPs, are used to screen for one or more desired biological activities or target proteins.

  本发明提供了用于分析蛋白质组的方法，例如细胞或裂解物。该分析基于具有特异性对蛋白质的活性形式的探针的使用，特别是酶和受体。这些探针可以通过不同的方式进行识别。根据本发明，提供了一种用于生成和筛选化合物库的方法，用于识别引物分子，并并行识别它们的生物学靶标。通过向一个或多个结合基团添加特定的功能性和/或基团，反应性功能性获得了对特定蛋白质和蛋白质类的结合亲和性和特异性。这种候选化合物库，本文称为活性探针（ABPs），用于筛选一个或多个所需的生物活性或靶标蛋白质。
• BISARYL COMPOUND AND MEDICAMENT FOR CANCER TREATMENT COMPRISING THE SAME
  申请人：——

  公开号：US20030018070A1

  公开（公告）日：2003-01-23

  A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar 1 —S—R 1 —S—Ar 2 wherein R 1 represents a nonmetal bridging group; Ar 1 and Ar 2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

  一种治疗癌症的药物，包括以下通用公式（I）所代表的化合物或其生理上可接受的盐：Ar1—S—R1—S—Ar2其中R1代表非金属桥接基团；Ar1和Ar2独立地代表从芳基组中选择的一种组，该芳基组在其环上具有一个至三个羟基，可选地被一价基团取代，并且该芳基组在其环上可能有一个至三个除羟基外的取代基；以及在其环上具有一个至三个羟基的杂环芳基组，可选地被一价基团取代，并且该杂环芳基组在其环上可能有一个至三个除羟基外的取代基。
• METAL COORDINATION COMPOUND AND LIGHT-EMITTING MATERIAL CONTAINING THE SAME
  申请人：Konno Hideo

  公开号：US20100317858A1

  公开（公告）日：2010-12-16

  To provide a light-emitting device that is capable of red-light-emitting with high luminance and high efficiency and that is excellent in endurance; and a metal coordination compound metal coordination compound having a partial structure represented by formula (1) that can be used in the light-emitting device, and that can also be used in applications, such as organic electroluminescent device materials, electrochemiluminescence (ECL) device materials, emission sensors, photosensitizers, displays, photographic materials, laser dyes, color filter dyes, optical communications, color conversion filters, backlights, illuminations, photosensitizing dyes, various light sources, and the like.

  提供一种具有高亮度和高效率的红光发射能力、并且具有出色耐久性的发光装置；以及具有由公式（1）表示的部分结构的金属配位化合物，可用于发光装置中，并可用于有机电致发光器件材料、电化学发光（ECL）器件材料、发射传感器、光敏剂、显示器、摄影材料、激光染料、彩色滤光片染料、光通信、色彩转换滤光片、背光、照明、光敏染料、各种光源等应用中。
• Bisaryl compound and medicament for cancer treatment comprising the same
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：US20030199560A1

  公开（公告）日：2003-10-23

  A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar 1 —S—R 1 —S—Ar 2 wherein R 1 represents a nonmetal bridging group; Ar 1 and Ar 2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.

  一种用于治疗癌症的药物，包含下述一般式（I）所表示的化合物或其生理上可接受的盐：Ar1—S—R1—S—Ar2其中，R1表示非金属桥接基团；Ar1和Ar2独立表示从以下组成的群体中选择的一种群体：在其环上具有一到三个羟基的芳基基团，该芳基基团可以选择性地被单价基团取代，并且该芳基基团的环上可能有一到三个除羟基外的取代基；以及在其环上具有一到三个羟基的杂环基团，该杂环基团可以选择性地被单价基团取代，并且该杂环基团的环上可能有一到三个除羟基外的取代基。